Evidence map›Paper›PMID 34985325›Full record

ReviewClinical microbiology reviews2022

A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.

Shokufeh Ghasemian Sorboni, Hanieh Shakeri Moghaddam, Reza Jafarzadeh-Esfehani, Saman Soleimanpour

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical microbiology reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 303 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
303citing papers in PubMed, 5 pooled it
39.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

303 citing papers in PubMed, 5 syntheses or guidelines pooled it, 477 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

243 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Shokufeh Ghasemian SorboniDepartment of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran.
Hanieh Shakeri MoghaddamDepartment of Biological Sciences, Simon Fraser University, Burnaby, Canada.
Reza Jafarzadeh-EsfehaniBlood Borne Infectious Research Center, Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi, Mashhad, Iran.
Saman SoleimanpourAntimicrobial Resistance Research Centre, Bu-Ali Research Institute, Mashhad University of Medical Sciencesgrid.411583.a, Mashhad, Iran.ORCID 0000-0003-3166-8292
Mashhad University of Medical Sciences · IRSimon Fraser University · CAUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human body is full of an extensive number of commensal microbes, consisting of bacteria, viruses, and fungi, collectively termed the human microbiome. The initial acquisition of microbiota occurs from both the external and maternal environments, and the vast majority of them colonize the gastrointestinal tract (GIT). These microbial communities play a central role in the maturation and development of the immune system, the central nervous system, and the GIT system and are also responsible for essential metabolic pathways. Various factors, including host genetic predisposition, environmental factors, lifestyle, diet, antibiotic or nonantibiotic drug use, etc., affect the composition of the gut microbiota. Recent publications have highlighted that an imbalance in the gut microflora, known as dysbiosis, is associated with the onset and progression of neurological disorders. Moreover, characterization of the microbiome-host cross talk pathways provides insight into novel therapeutic strategies. Novel preclinical and clinical research on interventions related to the gut microbiome for treating neurological conditions, including autism spectrum disorders, Parkinson's disease, schizophrenia, multiple sclerosis, Alzheimer's disease, epilepsy, and stroke, hold significant promise. This review aims to present a comprehensive overview of the potential involvement of the human gut microbiome in the pathogenesis of neurological disorders, with a particular emphasis on the potential of microbe-based therapies and/or diagnostic microbial biomarkers. This review also discusses the potential health benefits of the administration of probiotics, prebiotics, postbiotics, and synbiotics and fecal microbiota transplantation in neurological disorders.

Indexed as

Gastrointestinal MicrobiomeNervous System DiseasesProbioticsSynbioticsDysbiosisHumansPrebioticsPrebioticsfecal-microbiota transplantationgut microbiotaneurodegenerative disordersneuropsychiatric disordersprobiotic

Identifiers

PMID34985325
PMCPMC8729913
OpenAlexW4205459581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.